Merck unveils results from Phase 2 trial of V114 vaccine in infants
Category: #health  By Pankaj Singh  Date: 2019-05-10
  • share
  • Twitter
  • Facebook
  • LinkedIn

Merck unveils results from Phase 2 trial of V114 vaccine in infants

V114 has secured a Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) to avert invasive pneumococcal disease (IPD) in January 2019.

The U.S. based multinational pharmaceutical company Merck, also known as MSD outside Canada and the United States, has reportedly announced the results from a Phase 2 trial evaluating the immunogenicity, safety, and tolerability of V114. The experimental 15-valent pneumococcal conjugate vaccine of the company, in comparison with the currently available 13-valent pneumococcal conjugate vaccine (PCV13) in healthy infants 6-12 weeks of age.

Reportedly, in the trial, selected V114-008, V114 intersected its primary endpoint for the 13 serotypes contained in both the vaccines by indicating noninferiority. V114 also brought on an immune reaction in newborns for two additional serotypes, 22F and 33F, causing diseases.  These serotypes are not contained in PCV13.

V114 has secured a Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) to avert invasive pneumococcal disease (IPD) in January 2019. IPD is triggered in pediatric patients aging from 6 weeks to 18 years by the vaccine serotypes. The decision of FDA was partially informed by immunogenicity data from this Phase 2 study, the Phase 1/2 V114-005 study and V114-008 in healthy adults and infants. The outcomes of the V114-008 study were shown during an oral session at the 37thAnnual Meeting of the European Society for Pediatric Infectious Diseases (ESPID) in Ljubljana, Slovenia, and strengthen continued progression of Phase 3 clinical studies with V114.

V114-008, a double-blind, randomized, Phase 2 trial, compared the tolerability, immunogenicity, and safety of two distinct clinical lots of V114 (n=350 for lot 1; n=347 for lot 2) to PCV13 (n=347) in around 1,050 healthy infants aging two, four, six and 12-15 months. In the study, the percentage of subjects attaining the upper limit of immune reaction (IgG≥0.35 mcg/mL) accepted by WHO with lot of V114 was noninferior to the percentage observed with PCV13 for the 13 serotypes shared between the two vaccines.

Source credit: https://www.businesswire.com/news/home/20190508005210/en/Merck-Announces-Results-Phase-2-Trial-Investigational

https://www.mrknewsroom.com/news-release/research-and-development-news/merck-announces-results-phase-2-trial-investigational-15-



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

US buys all of the global supply of Gilead’s COVID-19 drug remdesivir
US buys all of the global supply of Gilead’s COVID-19 drug remdesivir
By Pankaj Singh

While top-notch companies are racing to develop a vaccine for COVID-19, it looks like the United States has secured almost all of the world’s supply of interim drug remdesivir to treat patients with COVID-19.

...

Potential COVID-19 vaccine by Bharat Biotech to enter clinical trials
Potential COVID-19 vaccine by Bharat Biotech to enter clinical trials
By Pankaj Singh

Bharat Biotech International, a leading Indian biotechnology company, has reportedly announced that its potential coronavirus vaccine, Covaxin, has received Drug Controller General of India (DCGI) approval to start hum...

Seattle Genetics reveals positive data from tisotumab vedotin trial
Seattle Genetics reveals positive data from tisotumab vedotin trial
By Pankaj Singh

Seattle Genetics, Inc., a renowned biotechnology firm that focuses on developing antibody-based cancer treatments, has recently revealed positive topline data from its Phase 2 clinical trial (innovaTV 204) assessing ti...